UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/553,946	10/21/2005	Atsushi Tendo	740709-544	5815
22204 NIXON PEABO	7590 03/06/200 ODY, LLP	EXAMINER		
401 9TH STRE		GALLIS, DAVID E		
SUITE 900 WASHINGTON, DC 20004-2128			ART UNIT	PAPER NUMBER
			1625	
			MAIL DATE	DELIVERY MODE
			03/06/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Comments	10/553,946	TENDO ET AL.				
Office Action Summary	Examiner	Art Unit				
	DAVID E. GALLIS	1625				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 04 No	ovember 2008					
· · · · · · · · · · · · · · · · · · ·	<u> </u>					
<i>,</i> —	, _					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
diesed in assertantes with the practice and a	x parte quayre, 1000 o.b. 11, 10	0.0.210.				
Disposition of Claims						
4)⊠ Claim(s) <u>3,4 and 7</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) 7 is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
· · · · · · · · · · · · · · · · · · ·						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ■ Some * c) ■ None of:						
·— <u> </u>	have been received					
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
_ .	3. Copies of the certified copies of the priority documents have been received in this National Stage					
	application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date						
S) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application 6) Other:						
т арет тио(э/ниан Date						

Application/Control Number: 10/553,946 Page 2

Art Unit: 1625

1.

2. The final rejection is withdrawn.

Claims 3, 4 and 7 are pending. Claims 1, 2, 5 and 6 have been canceled.
 Applicant's claim to foreign priority from application Japan 2003-121103 filed April 25,
 2003 is acknowledged. Applicant's amendments and arguments filed after final on
 November 4, 2008 have been entered and carefully considered.

Prior Rejections

4. With regard to the prior rejection of claims 1, 2, 5 and 6 under 35 U.S.C. 102(a) and (e), Applicants have canceled claims 1, 2, 5 and 6 outright. Therefore the rejection of claims 1, 2, 5 and 6 as anticipated by Nomura et al. is hereby withdrawn.

Claim Rejections - 35 USC § 103

- 5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 6. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Nomura et al.,US 6,387,908 B1, May 14, 2002 ('908), and their application 09/508026 filed May 5, 2000, and in further view of Stahl et al. (Handbook of Pharmaceutical Salts, Properties, Selection, and Use.,Verlag Helvetica Chimica Acta, Zurch, 2002).
- 7. Claim 7 is drawn organic amine salts of (2S,3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylate, including piperazine, arginine, lysine, and benzathine. Nomura et al. teach the same epoxysuccinamide derivative (Table 1,

Application/Control Number: 10/553,946

Art Unit: 1625

Column 9, Compound No. 87) and further teach that the base of this derivative can form organic amine salts reciting "The epoxysuccinamide derivative of the invention can be employed in the form of a physiologically acceptable salt. For example, in the case that R^1 is a hydrogen atom and X is -O--, it forms a salt with an alkali metal (e.g., sodium or potassium), an alkaline earth metal (e.g., calcium), or an organic amine". However, Nomura et al does not specifically teach the instantly claimed organic amine counter ions. Stahl et al. remedies the deficiency of Nomura et al. by teaching, as general reference in the art, piperazine, arginine, lysine, and benzathine organic salts, and thereby establishing these organic amines as counter ions that are well known in the art and obvious to one of ordinary skill in the art (see piperazine: pages 142, 215, 267, 321, 343, 345; arginine: pages 142, 215, 267, 311, 342-345; lysine: pages 215, 262, 267, 319, 344, 345; benzathine: pages 164, 168, 267, 312). While the use of these salts are novel to the process claimed, the salts themselves are obvious to one of ordinary skill in the art.

Page 3

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to David E. Gallis whose telephone number is 571-272-9068. The examiner can normally be reached on Mon-Thur 8:30-7:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on 571-272-1600. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

Application/Control Number: 10/553,946 Page 4

Art Unit: 1625

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/

David E. Gallis
Patent Examiner

/ Bernard Dentz/

Primary Examiner, Art Unit 1625